MicroRNA-301a modulates doxorubicin resistance in osteosarcoma cells by targeting AMP-activated protein kinase alpha 1

Biochemical and Biophysical Research Communications

Volumn 459, Issue 3, 2015, Pages 367-373

  Zhang, Yuanmin ^a,b   Duan, Guoqing ^b   Feng, Shiqing ^a  

^a TIANJIN MEDICAL UNIVERSITY   (China)

^b JINING MEDICAL UNIVERSITY   (China)

Author keywords

AMPK 1; Doxorubicin; Drug resistance; HMGCR; MicroRNA 301a; Osteosarcoma

Indexed keywords

ANTINEOPLASTIC AGENT; DOXORUBICIN; HMGCR PROTEIN, HUMAN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; MICRORNA; MIRN301 MICRORNA, HUMAN; PRKAA1 PROTEIN, HUMAN;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; BONE NEOPLASMS; CASE CONTROL STUDY; DRUG EFFECTS; DRUG RESISTANCE; GENE EXPRESSION REGULATION; GENETICS; HUMAN; METABOLISM; OSTEOSARCOMA; TUMOR CELL LINE; UPREGULATION;

AMP-ACTIVATED PROTEIN KINASES; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE NEOPLASMS; CASE-CONTROL STUDIES; CELL LINE, TUMOR; DOXORUBICIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION REGULATION, ENZYMOLOGIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; MICRORNAS; OSTEOSARCOMA; UP-REGULATION;

EID: 84931356396     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2015.02.101     Document Type: Article

References (38)

1. L. Endo-Munoz, A. Cumming, S. Sommerville, I. Dickinson, and N.A. Saunders Osteosarcoma is characterised by reduced expression of markers of osteoclastogenesis and antigen presentation compared with normal bone Br. J. Cancer 103 2010 73 81
2. A.J. Chou, and R. Gorlick Chemotherapy resistance in osteosarcoma: current challenges and future directions Expert Rev. Anticancer Ther. 6 2006 1075 1085
3. J. Huang, J. Ni, and K. Liu HMGB1 promotes drug resistance in osteosarcoma Cancer Res. 72 2012 230 238
4. A. McTiernan, R.C. Jinks, and M.R. Sydes Presence of chemotherapy-induced toxicity predicts improved survival in patients with localised extremity osteosarcoma treated with doxorubicin and cisplatin: a report from the European Osteosarcoma Intergroup Eur. J. Cancer 48 2012 703 712
5. V. Saini, C.D. Hose, and A. Monks Identification of CBX3 and ABCA5 as putative biomarkers for tumor stem cells in osteosarcoma PLoS One 7 2012 e41401
6. G. Moriceau, A.J. Roelofs, and R. Brion Synergistic inhibitory effect of apomine and lovastatin on osteosarcoma cell growth Cancer 118 2012 750 760
7. Y. Ma, Y. Ren, and E.Q. Han Inhibition of the Wnt-β-catenin and Notch signaling pathways sensitizes osteosarcoma cells to chemotherapy Biochem. Biophys. Res. Commun. 431 2013 274 279
8. E. Kobayashi, F.J. Hornicek, and Z. Duan MicroRNA involvement in osteosarcoma Sarcoma 2012 2012 359739
9. C.M. Croce Causes and consequences of microRNA dysregulation in cancer Nat. Rev. Genet. 10 2009 704 714
10. S. Griffiths-Jones, H.K. Saini, S. van Dongen, and A.J. Enright miRBase: tools for microRNA genomics Nucleic Acids Res. 36 2008 154 158
11. A. Markou, I. Sourvinou, P.A. Vorkas, G.M. Yousef, and E. Lianidou Clinical evaluation of microRNA expression profiling in non small cell lung cancer Lung Cancer 81 2013 388 396
12. A.C. Godfrey, Z. Xu, and C.R. Weinberg Serum microRNA expression as an early marker for breast cancer risk in prospectively collected samples from the sister study cohort Breast Cancer Res. 15 2013 R42
13. A. Schaefer, M. Jung, and H.J. Mollenkopf Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma Int. J. Cancer 126 2010 1166 1176
14. J. Guo, Y. Miao, and B. Xiao Differential expression of microRNA species in human gastric cancer versus non-tumorous tissues J. Gastroenterol. Hepatol. 24 2009 652 657
15. N.A. Schultz, J. Werner, and H. Willenbrock MicroRNA expression profiles associated with pancreatic adenocarcinoma and ampullary adenocarcinoma Mod. Pathol. 25 2012 1609 1622
16. H.M. Namløs, L.A. Meza-Zepeda, T. Barøy, and I.H. ∅stensen Modulation of the osteosarcoma expression phenotype by microRNAs PLoS One 7 2012 e48086
17. Y. Zhou, Z. Huang, S. Wu, X. Zang, M. Liu, and J. Shi miR-33a is up-regulated in chemoresistant osteosarcoma and promotes osteosarcoma cell resistance to cisplatin by down-regulating TWIST J. Exp. Clin. Cancer Res. 33 2014 12
18. B. Song, Y. Wang, and Y. Xi Mechanism of chemoresistance mediated by miR-140 in human osteosarcoma and colon cancer cells Oncogene 28 2009 4065 4074
19. B. Song, Y. Wang, and M.A. Titmus Molecular mechanism of chemoresistance by miR-215 in osteosarcoma and colon cancer cells Mol. Cancer 9 2010 96
20. H. Yu, H. Li, and H. Qian Upregulation of miR-301a correlates with poor prognosis in triple-negative breast cancer Med. Oncol. 31 2014 283
21. F. Ma, J. Zhang, and L. Zhong Upregulated microRNA-301a in breast cancer promotes tumor metastasis by targeting PTEN and activating Wnt/β-catenin signaling Gene 535 2014 191 197
22. M. Wang, C. Li, and B. Yu Overexpressed miR-301a promotes cell proliferation and invasion by targeting RUNX3 in gastric cancer J. Gastroenterol. 48 2013 1023 1033
23. J. Liu, G. Xian, and M. Li Cholesterol oxidase from Bordetella species promotes irreversible cell apoptosis in lung adenocarcinoma by cholesterol oxidation Cell. Death Dis. 5 2014 e1372
24. R. Crespo, S. Montero Villegas, M.C. Abba, M.G. de Bravo, and M.P. Polo Transcriptional and posttranscriptional inhibition of HMGCR and PC biosynthesis by geraniol in Hep-G2 cell proliferation linked pathways Biochem. Cell. Biol. 91 2013 131 139
25. Y. Liu, L. Zhao, and Y. Ju A novel androstenedione derivative induces ROS-mediated autophagy and attenuates drugresistance in osteosarcoma by inhibiting macrophage migration inhibitory factor (MIF) Cell. Death Dis. 5 2014 e1361
26. P.R. Clarke, and D.G. Hardie Regulation of HMG-CoA reductase: identification of the site phosphorylated by the AMP-activated protein kinase in vitro and in intact rat liver EMBO J. 9 1990 2439 2446
27. M. Bhandaru, M. Martinka, G. Li, and A. Rotte Loss of AMPKα1 expression is associated with poor survival in melanoma patients J. Invest Dermatol 134 2014 1763 1766
28. J.J. Park, S.M. Seo, and E.J. Kim Berberine inhibits human colon cancer cell migration via AMP-activated protein kinase-mediated downregulation of integrin β1 signaling Biochem. Biophys. Res. Commun. 426 2012 461 467
29. Y.K. Lee, S.Y. Park, and Y.M. Kim Suppression of mTOR via Akt-dependent and -independent mechanisms in selenium-treated colon cancer cells: involvement of AMPKalpha1 Carcinogenesis 31 2010 1092 1099
30. Y.K. Lee, W.S. Lee, G.S. Kim, and O.J. Park Anthocyanins are novel AMPKα1 stimulators that suppress tumor growth by inhibiting mTOR phosphorylation Oncol. Rep. 24 2010 1471 1477
31. Y.C. Chiu, D.C. Shieh, and K.M. Tong Involvement of AdipoR receptor in adiponectin-induced motility and alpha2beta1 integrin upregulation in humanchondrosarcoma cells Carcinogenesis 30 2009 1651 1659
32. S. Wang, P. Song, and M.H. Zou Inhibition of AMP-activated protein kinase α (AMPKα) by doxorubicin accentuates genotoxic stress and cell death in mouse embryonic fibroblasts and cardiomyocytes: role of p53 and SIRT1 J. Biol. Chem. 287 2012 8001 8012
33. Y.C. Li, M.J. Park, S.K. Ye, C.W. Kim, and Y.N. Kim Elevated levels of cholesterol-rich lipid rafts in cancer cells are correlated with apoptosis sensitivity induced by cholesterol-depleting agents Am. J. Pathol. 168 2006 1107 1118
34. L. Zhuang, J. Kim, R.M. Adam, K.R. Solomon, and M.R. Freeman Cholesterol targeting alters lipid raft composition and cell survival in prostate cancer cells and xenografts J. Clin. Invest 115 2005 959 968
35. Z. Cao, H. Fan-Minogue, and D.I. Bellovin MYC phosphorylation, activation, and tumorigenic potential in hepatocellular carcinoma are regulated by HMG-CoA reductase Cancer Res. 71 2011 2286 2297
36. K.K. Chan, A.M. Oza, and L.L. Siu The statins as anticancer agents Clin. Cancer Res. 9 2003 10 19
37. M.D. Siperstein Cholesterol, cholesterogenesis and cancer Adv. Exp. Med. Biol. 369 1995 155 166
38. M. Liscovitch, and Y. Lavie Multidrug resistance: a role for cholesterol efflux pathways? Trends Biochem. Sci. 25 2000 530 534